OBJECTIVES: Pharmacoeconomics analysis of SMART (Symbicort Maintenance and Reliever Therapy) in compare to treatment with Seretide Multidisc and to routine therapy of BA in Russia. METHODS: An incremental cost-effectiveness analysis of three scenarios for BA drug therapy was done: 1) SMART (Symbicort (Budesonide/Formoterol) 320/9 or 640/18 ìg/day + Symbicort 160/4,5 ìg/day as needed); 2) Seretide ((Fluticasone/Salmeterol) treatment (from 200/100 ìg/day to 1000/100 ìg/day) in combination with Salbutamol as needed; and 3) Routine BA therapy Comparison of SMART vs Seretide treatment was based on the results of COSMOS study - randomized study, 2143 patients with BA from 16 countries, follow-up period 52 weeks. Routine practice was based on the results of local pharmacoepidemiological study of outpatient treatment, 1362 patients from 20 RF regions. The study gathered information of the type of drug therapy, health care system (HC) resources for 1 year. Values of following ICER were compared: 1) Difference between costs of HC resources per one additionally invested ruble, required for a given treatment scenario 1 or 2 vs routine therapy: {HC costs (scenario) – HC costs (routine therapy)}/{DT cost (scenario) – DT cost (routine therapy)} DT – Drug Therapy, and 2)Difference between BA burden per one additionally invested ruble, required for a given treatment scenario 1 or 2 vs routine therapy: {BA burden (scenario) –BA burden (routine therapy)}/{DT cost (scenario) – DT cost (routine therapy)} RESULTS: Switching of patients from routine treatment to SMART would reach the reduction of BA burden by 57 thousand rubles/pt/year depending on length of hospitalization and in some regions it could be 78,000 rubles/pt/year. CONCLUSION: SMART in BA treatment is more preferable compared to the routine therapy and treatment by Seretide.